Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3.9% Rapamycin Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics has announced the planned pivotal Phase 3 study design for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in the treatment of Microcystic Lymphatic Malformations. The announcement was made by the clinical-stage biopharmaceutical company, which aims to address the lack of FDA-approved therapies for this rare genetic disease. The Phase 2 results demonstrated signifi..